secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039389
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated
--------------------------------------------------------------------------------

- Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.
- Net loss Q2 2023: $44.1M vs $34.9M Q2 2022; R&D $38.9M vs $29.5M.
- Phase 3 PEAK lead-in data: 55% DCR; 100% DCR and 17% ORR in evaluable 2nd-line GIST patients.
- Selected FGFR2 kinase inhibitor as first internally developed candidate; preclinical data planned for 2H2023.
- Initial SUMMIT (NonAdvSM) and updated APEX (AdvSM) data expected in second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/0000950170-23-039389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/cogt-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer